New drug combo tested for tough cancers
NCT ID NCT06544655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colon, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0003
Tucson, Arizona, 85719, United States
-
Local Institution - 0004
Sioux Falls, South Dakota, 57104, United States
-
Local Institution - 0007
Los Angeles, California, 90033, United States
-
Local Institution - 0011
Grand Rapids, Michigan, 49546, United States
-
Local Institution - 0013
San Antonio, Texas, 78229, United States
-
Local Institution - 0016
Montreal, Quebec, H2X 0A9, Canada
-
Local Institution - 0017
Toronto, Ontario, M5G 2M9, Canada
-
Local Institution - 0019
Elizabeth Vale, South Australia, 5112, Australia
-
Local Institution - 0021
Darlinghurst, New South Wales, 2010, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?